Bicycle Therapeutics plc (BCYC) announced on Monday the updated topline Phase 1 combination data for its zelenectide pevedotin alongside pembrolizumab. This study specifically targets untreated cisplatin-ineligible patients with metastatic urothelial cancer (mUC). As a result, the company’s stock saw a 13% increase.
In addition, Bicycle Therapeutics highlighted recent achievements and laid out its strategic priorities and anticipated milestones for the year 2025.
“In 2024, Bicycle Therapeutics achieved substantial progress across all facets of our operations. Specifically, we made significant clinical strides with our targeted therapies in solid tumors. This includes markedly increasing the pool of patients who could potentially benefit from our leading therapy, zelenectide pevedotin. We also advanced our pipeline of novel radiopharmaceuticals and bolstered our financial standing and operational capabilities to support our strategic goals," stated CEO Kevin Lee.
Zelenectide pevedotin, a Bicycle Toxin Conjugate, shows considerable promise in treating Nectin-4 cancers, exhibiting a 65% overall response rate (ORR) among all patients assessed for efficacy, and a 50% ORR among those with confirmed responses.
The material has been provided by InstaForex Company - www.instaforex.com
In addition, Bicycle Therapeutics highlighted recent achievements and laid out its strategic priorities and anticipated milestones for the year 2025.
“In 2024, Bicycle Therapeutics achieved substantial progress across all facets of our operations. Specifically, we made significant clinical strides with our targeted therapies in solid tumors. This includes markedly increasing the pool of patients who could potentially benefit from our leading therapy, zelenectide pevedotin. We also advanced our pipeline of novel radiopharmaceuticals and bolstered our financial standing and operational capabilities to support our strategic goals," stated CEO Kevin Lee.
Zelenectide pevedotin, a Bicycle Toxin Conjugate, shows considerable promise in treating Nectin-4 cancers, exhibiting a 65% overall response rate (ORR) among all patients assessed for efficacy, and a 50% ORR among those with confirmed responses.
The material has been provided by InstaForex Company - www.instaforex.com